Stryker Co. (NYSE:SYK) Stock Holdings Boosted by 626 Financial LLC

626 Financial LLC boosted its stake in Stryker Co. (NYSE:SYK - Free Report) by 35.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,278 shares of the medical technology company's stock after acquiring an additional 21,090 shares during the period. Stryker comprises approximately 15.4% of 626 Financial LLC's portfolio, making the stock its largest position. 626 Financial LLC's holdings in Stryker were worth $29,883,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Elefante Mark B purchased a new stake in Stryker in the fourth quarter valued at $337,000. Appleton Partners Inc. MA raised its holdings in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares during the last quarter. Metis Global Partners LLC raised its holdings in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after buying an additional 1,561 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of Stryker by 415.8% in the fourth quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company's stock valued at $8,664,000 after buying an additional 19,356 shares during the last quarter. Finally, US Bancorp DE raised its holdings in shares of Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after buying an additional 976 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research reports. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a report on Tuesday, March 4th. JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Citigroup restated a "buy" rating and issued a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Roth Mkm raised their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Price Performance

Shares of SYK stock traded up $1.05 during trading hours on Friday, hitting $384.15. The company's stock had a trading volume of 709,048 shares, compared to its average volume of 1,331,290. The business has a fifty day moving average of $370.10 and a 200-day moving average of $376.03. The stock has a market cap of $146.63 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.93 and a beta of 0.91. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.50 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.